Melbourne-based MedTech, 4Dx, has published results validating its technology’s potential to play a game-changing role in the diagnostics and treatment for respiratory diseases such as cystic fibrosis, lung cancer, asthma, and black lung.
The results of a new pre-clinical study, show that 4Dx’s breakthrough four-dimensional lung diagnostic platform has the ability to better measure the progression and severity of cystic fibrosis (CF) like lung disease – something that is critically lacking in today’s care of patients with lung disease.
This result is a critical step towards the commercialisation of the technology for clinical benefit to current sufferers of respiratory disease.
Steve Peuschel, Executive Director of 4Dx, born with Cystic Fibrosis, and in 2003 was the recipient of a double lung transplant, understands the urgency for earlier detection and for doctors to be able to see what is really important – how the lungs work.
“The problem with current lung diagnostics is that if you have something happening in one airway of the lung, the rest of the lung compensates. So with current diagnostics, you can get fairly normal results on the tests even when disease is progressing,” says Peuschel.
“Our technology provides images of the breathing lungs, allowing investigators to, for the first time, view and measure subtle changes in ventilation to specific areas of the lung as the disease progresses”
The significant results have fueled hopes among clinicians, including Professor Greg Snell, Head of Lung Transplant Service at the Alfred hospital, for major improvement in treating lung disease.
“This technology has great potential as a new tool for both early diagnosis and management of many very common lung conditions. I think this will be the start of a new way of thinking about diagnostic imaging,” says Snell.
Whilst there is no cure for CF, Karin Knoester, CEO of Cystic Fibrosis Victoria says the CF community is always interested in adding to the arsenal of tools currently used to help their members treat and manage their condition.
“Any tool that can identify damage at an early stage will be able to inform intervention, with the hope of reducing further damage.”
“Equally, anything that can more precisely measure the progression of the disease in the lung and improve outcomes is valuable to our members,” says Knoester.
The research represents a collaboration between leading CF scientists and physicians from Australia, The United states, Germany and 4Dx. Key results of this study are published today in the international journal Scientific Reports.
Read the original press release here.